Curative effect and safety of decitabine combined with HAG for patients with myelodysplastic syndromes / 药物评价研究

ABSTRACT

Objective To explore the curative effect and safety of decitabine combined with HAG for patients with myelodysplastic syndromes.Methods Fifty-six patients with myelodysplastic syndromes in Nanyang Second General Hospital from August 2014 to August 2016 were divided randomly into control group (n =26,accepted HAG chemotherapy) and study group (n =30,adopted decitabine combined with HAG) to compare the clinical curative and the incidence of adverse reactions between two groups.Results After a course of treatment,the total remission of control group was 26.9％,and study group was 30％,and difference was no significance between two groups.After two courses of treatment,the total remission of study group (83.3％) was higher significantly than those of control group (57.7％).The case of adverse reactions of study group (25 cases) was lower than control group significantly (P ＜ 0.05).Conclusions Decitabine assisted HAG chemotherapy could improve the clinical curative effect remarkably for patients myelodysplastic syndromes,which deserved popularization in clinic duo to the decreasing incidence of adverse reactions and the well quality of life.